+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and activity of barzolvolimab compared to a placebo in adults with cold induced urticaria ColdU or symptomatic dermographism SD who continue to have symptoms despite using H1-antihistamines. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand treatment options for these chronic skin conditions. Participants will first undergo a screening period lasting up to 4 weeks. Following this, there is a 24-week treatment phase where participants receive either barzolvolimab or a placebo. Those receiving barzolvolimab get a 450mg injection at the start, then 150mg every 4 weeks. After this, all participants receive 300mg barzolvolimab every 8 weeks for 28 weeks. Finally, there is a 16-week follow-up period where participants are observed without treatment. During the study, participants will complete daily symptom diaries and attend regular visits for assessments. Researchers will measure responses to provocation testing at various time points, clinical symptoms like itch and hives, and changes in temperature and friction thresholds. Quality of life related to dermatology will also be evaluated. Safety and tolerability are monitored throughout the study, which lasts over a year from screening to follow-up.

Age: 18Years +All GendersPhase 3
72 locations